Ascendis Pharma A/S (NASDAQ:ASND) Shares Bought by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 35.3% during the 3rd quarter, Holdings Channel reports. The firm owned 184,623 shares of the biotechnology company’s stock after buying an additional 48,120 shares during the period. Loomis Sayles & Co. L P’s holdings in Ascendis Pharma A/S were worth $27,566,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Signaturefd LLC lifted its stake in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter. Profund Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after acquiring an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC increased its position in Ascendis Pharma A/S by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 240 shares in the last quarter.

Ascendis Pharma A/S Stock Up 0.8 %

ASND opened at $130.85 on Tuesday. The firm’s 50 day moving average is $133.04 and its 200-day moving average is $132.17. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The firm has a market capitalization of $7.93 billion, a P/E ratio of -16.19 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Equities analysts expect that Ascendis Pharma A/S will post -7.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Wedbush restated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Wells Fargo & Company lifted their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Oppenheimer reduced their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, TD Cowen lowered their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.